The Asia Pacific Ablation Technologies market was valued at USD 741 Million in 2020. It is projected to reach USD 1501 Million by 2025, growing at a CAGR of 12.5% between 2020 to 2025.
Ablation technologies are majorly employed for surgical procedures in cardiology disorders such as atrial fibrillation, arrhythmia, refractory hypertension, and others; this removes cancerous and non-cancerous tumors also an important application of ablation devices.
The market for Ablation Technologies is mainly driven due to the increasing number of geriatric and obese populations because geriatric and obese populations are more prone to chronic diseases, increasing the use of minimally invasive surgery procedures, rising healthcare expenditure, emerging technologies for tumor management, and increasing prevalence of cardiovascular diseases. But the market growth can be hampered due to the reuse and reprocessing of devices in developing countries, stringent government regulations, and increased healthcare cost and containment measures.
The Ablation Technologies market in the Asia Pacific region is projected to grow at the highest CAGR, which is greatly due to the increasing popularity of minimally invasive surgeries in the region, government support to increase population access for elective surgeries, increasing investment by global players in the region.
This research report on the Asia Pacific Ablation Technologies Market has been segmented and sub-segmented into the following categories.
By Product:
By Type:
By Application:
By Country:
Based on type, the Radiofrequency-based ablation technology segment is expected to lead the European ablation technologies market.
Based on application, a large market share is attributed to the cardiovascular disease treatment segment.
Noteworthy Companies leading the Asia Pacific Ablation Technologies Market Profiled in the Report are Biosense Webster, Inc., St. Jude Medical, Inc., Boston Scientific Corporation, AngioDynamics, Inc., AtriCure, Inc., Smith & Nephew plc, Galil Medical Inc., CONMED Corporation, Olympus Corporation, Covidien PLC, Medtronic, Inc., and BSD Medical Corporation.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Light/Laser ablators
5.1.2.1 Excimer laser ablators
5.1.2.2 Cold laser ablators
5.1.3 Radiofrequency (RF) ablators
5.1.3.1 Temperature-controlled RF ablators
5.1.3.2 Fluid-cooled RF ablators
5.1.3.3 Robotic catheter manipulation systems
5.1.4 Electrical ablators
5.1.4.1 Argon plasma/beam coagulators
5.1.4.2 Irreversible electroporation ablators
5.1.5 Ultrasound ablators
5.1.5.1 High-intensity focused ultrasound (HIFU) ablators
5.1.5.2 Magnetic resonance guided focused ultrasound (MRGFUS) ablators
5.1.5.3 Ultrasonic surgical ablation systems
5.1.5.4 Extracorporeal shockwave lithotripsy systems
5.1.6 Microwave ablators
5.1.6.1 Microwave thermotherapy ablators
5.1.7 Cryoablation devices
5.1.7.1 Tissue contact probe ablators
5.1.7.2 Tissue spray probe ablators
5.1.7.3 Epidermal and subcutaneous cryoablation systems
5.1.8 Hydrothermal ablators
5.1.8.1 Endothermal hydrothermal balloon ablation devices
5.1.9 Y-o-Y Growth Analysis, By Product
5.1.10 Market Attractiveness Analysis, By Product
5.1.11 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Light/Laser Ablation
5.2.3 Radiofrequency Ablation
5.2.4 Electrical Ablation
5.2.5 Ultrasound Ablation
5.2.6 Cryoablation
5.2.7 Microwave Ablation
5.2.8 Hydrothermal Ablation
5.2.9 Y-o-Y Growth Analysis, By Type
5.2.10 Market Attractiveness Analysis, By Type
5.2.11 Market Share Analysis, By Type
5.3 Application
5.3.1 Introduction
5.3.2 Cardiovascular Disease Treatment
5.3.3 Cancer Treatment
5.3.4 Ophthalmologic Treatment
5.3.5 Gynecologic Treatment
5.3.6 Pain Management
5.3.7 Urologic Treatment
5.3.8 Orthopedic Treatment
5.3.9 Cosmetic Surgery
5.3.10 Other Treatments
5.3.11 Y-o-Y Growth Analysis, By Application
5.3.12 Market Attractiveness Analysis, By Application
5.3.13 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Biosense Webster, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 St. Jude Medical, Inc.
8.3 Boston Scientific Corporation
8.4 AngioDynamics, Inc.
8.5 AtriCure, Inc.
8.6 Smith & Nephew plc
8.7 Galil Medical Inc.
8.8 CONMED Corporation
8.9 Olympus Corporation
8.10 Covidien PLC
8.11 Medtronic, Inc.
8.12 BSD Medical Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Related Reports
